Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$296.75

-3.80 (-1.26%)

(As of 10/17/2024 ET)

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
6

Buy
18

Based on 24 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 6 have given a hold rating, and 18 have given a buy rating for ALNY.

Consensus Price Target

$286.82
-3.35% Downside

According to the 24 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $286.82. The highest price target for ALNY is $400.00, while the lowest price target for ALNY is $159.00. The average price target represents a forecasted downside of -3.35% from the current price of $296.75.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

ALNY Analyst Ratings Over Time

Type	Current Forecast 10/18/23 to 10/17/24	1 Month Ago 9/18/23 to 9/17/24	3 Months Ago 7/20/23 to 7/19/24	1 Year Ago 10/18/22 to 10/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$286.82	$279.14	$253.55	$234.76
Forecasted Upside	-3.35% Downside	1.70% Upside	6.61% Upside	42.21% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[Urgent] Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	-3.35% Downside	12,628.69% Upside	6.31% Upside
News Sentiment Rating	Neutral News See Recent ALNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/16/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$305.00	+6.14%
10/14/2024	Bank of America 4 of 5 stars		Boost Target	Buy ➝ Buy	$307.00 ➝ $314.00	+10.70%
10/11/2024	Chardan Capital 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00	+5.42%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$220.00 ➝ $220.00	-21.77%
10/10/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$300.00 ➝ $300.00	+9.81%
10/10/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00	+18.12%
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/30/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$400.00 ➝ $400.00	+52.61%
8/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$248.00 ➝ $280.00	+3.37%
8/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$198.00 ➝ $370.00	+40.85%
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$207.00 ➝ $233.00	-14.17%
8/2/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$242.00 ➝ $275.00	+2.10%
8/2/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$291.00 ➝ $342.00	+24.91%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$291.00 ➝ $295.00	+12.94%
8/2/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$357.00 ➝ $366.00	+36.26%
7/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$250.00 ➝ $255.00	-3.04%
6/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$253.00 ➝ $288.00	+18.37%
6/27/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$215.00 ➝ $295.00	+20.32%
6/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$260.00 ➝ $282.00	+18.57%
6/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$138.00 ➝ $159.00	-33.15%
6/25/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$210.00 ➝ $260.00	+12.40%
6/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$234.00 ➝ $234.00	+3.28%
4/8/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
12/14/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$210.00 ➝ $217.00	+15.12%
10/11/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$237.00 ➝ $218.00	+28.97%
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$220.00	+8.83%
2/21/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$304.00	+48.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:31 PM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 8, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

Alnylam Pharmaceuticals, Inc. reported a significant increase in revenue, up 107.0% year-over-year, indicating strong growth potential.
The company beat analysts' EPS estimates by $0.61, showcasing strong financial performance.
Analysts have set a high price target for Alnylam Pharmaceuticals, Inc., with a consensus target of $279.14, suggesting potential for stock price appreciation.
Insider buying activity has been observed, indicating confidence in the company's future prospects.
Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating positive sentiment towards the stock.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

Despite positive analyst ratings, there are still some hold ratings on the stock, suggesting potential risks or uncertainties.
Insiders have been selling shares of Alnylam Pharmaceuticals, Inc., which could be perceived as a lack of confidence in the company's future performance.
Stock price volatility may be a concern for investors, as the stock has experienced fluctuations in recent trading sessions.
Alnylam Pharmaceuticals, Inc. operates in the biopharmaceutical industry, which is highly competitive and subject to regulatory challenges.
While revenue growth has been strong, the company's EPS forecast for the current year is negative, indicating potential profitability challenges.

ALNY Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $286.82, with a high forecast of $400.00 and a low forecast of $159.00.
: 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.
: According to analysts, Alnylam Pharmaceuticals's stock has a predicted downside of -3.35% based on their 12-month stock forecasts.
: Over the previous 90 days, Alnylam Pharmaceuticals's stock had 1 upgrade by analysts.
: Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, Citigroup, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Raymond James, Royal Bank of Canada, Scotiabank, The Goldman Sachs Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Alnylam Pharmaceuticals less than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.75 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ALNY compares to other companies.